摘要
FOXO3a和FOXM1是两个在癌症的DNA损伤反应中起拮抗作用的叉头转录因子。FOXO3a的功能就像典型的肿瘤抑制基因,而FOXM1是一种遗传性癌症里强力的异常过度表达的致癌基因。FOXO3a不仅抑制FoxM1表达而且抑制其转录输出。最近的研究已经提出FOXO3a和FOXM1在DNA损伤反应起核心作用的新颖的见解。通过对DNA损伤的感应、调节、信号转导和修复来调节关键基因的表达调控、以及对细胞衰老,细胞周期和细胞死亡的控制,FOXO3a-FOXM1轴在DNA损伤修复和伴随的细胞反应中起着关键的作用。FOXO3a-FOXM1轴以此方式关键性地决定细胞的命运,即对基因毒性药物的反应和控制DNA修复和细胞坏死或衰老之间的平衡。因此,抑制癌细胞里的FOXM1或活化FOXO3a,可以降低DNA修复率和细胞存活率,同时增加细胞衰老和细胞死亡,来提高对DNA损伤的癌症治疗的疗效。从概念上论,靶点于Foxo3a和FOXM1的分子治疗方法有希望提高DNA损伤剂的疗效和选择性,特别对基因毒性剂抵抗的癌症的治疗。此外,FOXO3a,FOXM1及其下游转录目标也可能是可靠的诊断标志物,用以预测治疗方案选择的结果,和监测DNA损伤剂的治疗。
关键词: 癌症,DNA损伤,抗药性,FOXM1,FOXO3a,基因毒性剂,转录目标
Current Drug Targets
Title:Insights into a Critical Role of the FOXO3a-FOXM1 Axis in DNA Damage Response and Genotoxic Drug Resistance
Volume: 17 Issue: 2
Author(s): Gabriela Nestal de Moraes, Laura Bella, Stefania Zona, Matthew J. Burton and Eric W.-F. Lam
Affiliation:
关键词: 癌症,DNA损伤,抗药性,FOXM1,FOXO3a,基因毒性剂,转录目标
摘要: FOXO3a and FOXM1 are two forkhead transcription factors with antagonistic roles in cancer and DNA damage response. FOXO3a functions like a typical tumour suppressor, whereas FOXM1 is a potent oncogene aberrantly overexpressed in genotoxic resistant cancers. FOXO3a not only represses FOXM1 expression but also its transcriptional output. Recent research has provided novel insights into a central role for FOXO3a and FOXM1 in DNA damage response. The FOXO3a-FOXM1 axis plays a pivotal role in DNA damage repair and the accompanied cellular response through regulating the expression of genes essential for DNA damage sensing, mediating, signalling and repair as well as for senescence, cell cycle and cell death control. In this manner, the FOXO3a-FOXM1 axis also holds the key to cell fate decision in response to genotoxic therapeutic agents and controls the equilibrium between DNA repair and cell termination by cell death or senescence. As a consequence, inhibition of FOXM1 or reactivation of FOXO3a in cancer cells could enhance the efficacy of DNA damaging cancer therapies by decreasing the rate of DNA repair and cell survival while increasing senescence and cell death. Conceptually, targeting FOXO3a and FOXM1 may represent a promising molecular therapeutic option for improving the efficacy and selectivity of DNA damage agents, particularly in genotoxic agent resistant cancer. In addition, FOXO3a, FOXM1 and their downstream transcriptional targets may also be reliable diagnostic biomarkers for predicting outcome, for selecting therapeutic options, and for monitoring treatments in DNA-damaging agent therapy.
Export Options
About this article
Cite this article as:
Gabriela Nestal de Moraes, Laura Bella, Stefania Zona, Matthew J. Burton and Eric W.-F. Lam , Insights into a Critical Role of the FOXO3a-FOXM1 Axis in DNA Damage Response and Genotoxic Drug Resistance, Current Drug Targets 2016; 17 (2) . https://dx.doi.org/10.2174/1389450115666141122211549
DOI https://dx.doi.org/10.2174/1389450115666141122211549 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Angiogenesis: A Target for Cancer Therapy
Current Pharmaceutical Design Target Identification of Grape Seed Extract in Colorectal Cancer Using Drug Affinity Responsive Target Stability (DARTS) Technique: Role of Endoplasmic Reticulum Stress Response Proteins
Current Cancer Drug Targets The Epithelial-Stromal Interaction as a Potential Target for Breast Cancer Treatment
Clinical Cancer Drugs MiRNA-29: A microRNA Family with Tumor-Suppressing and Immune-Modulating Properties
Current Molecular Medicine VEGF, a Mediator of the Effect of Experience on Hippocampal Neurogenesis
Current Alzheimer Research β-Carboline Alkaloids: Biochemical and Pharmacological Functions
Current Medicinal Chemistry The Molecular Pathology of Eye Tumors: A 2019 Update Main Interests for Routine Clinical Practice
Current Molecular Medicine Calpain-Associated Proteolytic Regulation of the Stromal Microenvironment in Cancer
Current Pharmaceutical Design Identification and Characterization of New Proteins in Podocyte Dysfunction of Membranous Nephropathy by Proteomic Analysis of Renal Biopsy
Current Pharmacogenomics and Personalized Medicine Growing Collateral Arteries On Demand
Recent Patents on Cardiovascular Drug Discovery Current Advances in the Development of Anticancer Drugs Targeting Tyrosine Kinases of the Src Family
Current Drug Therapy Role of Drug Metabolism in the Cytotoxicity and Clinical Efficacy of Anthracyclines
Current Drug Metabolism The Role of Stress Proteins in Prostate Cancer
Current Genomics Glutaminase Isoenzymes as Key Regulators in Metabolic and Oxidative Stress Against Cancer
Current Molecular Medicine Mammalian Cell Competitions, Cell-in-Cell Phenomena and Their Biomedical Implications.
Current Molecular Medicine The Efficacy and Mechanism of Proteasome Inhibitors in Solid Tumor Treatment
Recent Patents on Anti-Cancer Drug Discovery Calorie Restriction and Dietary Restriction Mimetics: A Strategy for Improving Healthy Aging and Longevity
Current Pharmaceutical Design Emerging Biologics in the Treatment of Inflammatory Bowel Disease: What is Around the Corner?
Current Drug Targets Fibrate-Associated Adverse Effects Beyond Muscle and Liver Toxicity
Current Pharmaceutical Design Molecular Targets for Papillomavirus Therapy
Current Drug Targets - Infectious Disorders